TrialArthritis research & therapy2021

A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.

Kathleen Weisel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.